<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00564564</url>
  </required_header>
  <id_info>
    <org_study_id>968/05</org_study_id>
    <secondary_id>2005/55628-08</secondary_id>
    <nct_id>NCT00564564</nct_id>
  </id_info>
  <brief_title>Quetiapine Augmentation Versus Clomipramine Augmentation of SSRI for Obsessive-compulsive Disorder Patients</brief_title>
  <acronym>QCAT</acronym>
  <official_title>Quetiapine Augmentation Versus Clomipramine Augmentation of Selective Serotonin Reuptake Inhibitors for Obsessive-compulsive Disorder Patients That do Not Respond to a SSRI Trial: a Randomized Open-trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Sao Paulo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Conselho Nacional de Desenvolvimento Científico e Tecnológico</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Sao Paulo</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this trial is to compare in an open trial format the efficacy of association
      of clomipramine and quetiapine with SSRI after SSRI treatment failed to produce complete
      remission of obsessive compulsive disorder symptoms.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of this trial wis to compare in an randomized open trial format the efficacy of
      association of clomipramine at maximum dosage of 75mg per day and quetiapine at maximum
      dosage of 200mg per day with SSRI after SSRI treatment for 12 weeks failed to produce
      complete remission of OCD symptoms.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2006</start_date>
  <completion_date type="Actual">December 2007</completion_date>
  <primary_completion_date type="Actual">December 2007</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>YBOCS</measure>
    <time_frame>12 weeks</time_frame>
    <description>difference between initial and final (12 week) Yale Brown Obsessive Compulsive Scale (YBOCS)score</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>CGI</measure>
    <time_frame>12 weeks</time_frame>
    <description>Clinical Global Impression score for improvement at week 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerability</measure>
    <time_frame>weeks 0,2,4,8 and 12</time_frame>
    <description>adverse events measure (emphasis in serotonergic syndrome)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiotoxicity</measure>
    <time_frame>week 0 and 2</time_frame>
    <description>Changes in baseline (week 0) EKG regarding QT interval</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Obsessive Compulsive Disorder</condition>
  <arm_group>
    <arm_group_label>Quetiapine augmentation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Quetiapine up to 200mg/day plus SSRI at maximum tolerated or recommended dosage</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Clomipramine augmentation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Clomipramine up to 150mg/day plus SSRI at maximum tolerated or recommended dosage</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Quetiapine</intervention_name>
    <description>Quetiapine once a day at maximum dosage of 200mg per day asociated to a SSRI (maximum dosage of 40mg per day for fluoxetine; 200mg per day for sertraline and 60mg per day for citalopram)</description>
    <arm_group_label>Quetiapine augmentation</arm_group_label>
    <other_name>Seroquel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clomipramine</intervention_name>
    <description>Clomipramine once a day at maximum dosage of 75mg per day plus SSRI (maximum dosage of 40mg per day for fluoxetine; 200mg per day for sertraline and 60mg per day for citalopram)</description>
    <arm_group_label>Clomipramine augmentation</arm_group_label>
    <other_name>Anafranil</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  primary OCD diagnosis according to DSM IV criteria

          -  current symptoms were responsible for significant distress

          -  previous trial of at least 12 weeks with SSRI (being at least 8 weeks at maximum
             tolerated dosage) failed to produce full remission of OCD symptoms

        Exclusion Criteria:

          -  presence of clinical or neurological diseases that may be worsen by the medications
             included in treatment protocol

          -  current substance dependence or abuse,

          -  current psychotic symptoms

          -  current suicide risk

          -  and current pregnancy or intention to get pregnant before the end of the treatment
             protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Juliana B Diniz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Psychiatry University of São Paulo Medical School</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institute of Psychiatry, Clinics Hospital, University of São Paulo Medical School</name>
      <address>
        <city>São Paulo</city>
        <state>SP</state>
        <zip>05403-010</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <link>
    <url>http://www.ipqhc.org.br/</url>
    <description>institutional site</description>
  </link>
  <link>
    <url>https://www.ncbi.nlm.nih.gov/pubmed/19164490</url>
    <description>Mains results</description>
  </link>
  <reference>
    <citation>Bloch MH, Landeros-Weisenberger A, Kelmendi B, Coric V, Bracken MB, Leckman JF. A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder. Mol Psychiatry. 2006 Jul;11(7):622-32. Epub 2006 Apr 4. Review. Erratum in: Mol Psychiatry. 2006 Aug;11(8):795.</citation>
    <PMID>16585942</PMID>
  </reference>
  <reference>
    <citation>Browne M, Horn E, Jones TT. The benefits of clomipramine-fluoxetine combination in obsessive compulsive disorder. Can J Psychiatry. 1993 May;38(4):242-3.</citation>
    <PMID>8518974</PMID>
  </reference>
  <reference>
    <citation>Denys D, de Geus F, van Megen HJ, Westenberg HG. A double-blind, randomized, placebo-controlled trial of quetiapine addition in patients with obsessive-compulsive disorder refractory to serotonin reuptake inhibitors. J Clin Psychiatry. 2004 Aug;65(8):1040-8.</citation>
    <PMID>15323587</PMID>
  </reference>
  <reference>
    <citation>Fineberg NA, Sivakumaran T, Roberts A, Gale T. Adding quetiapine to SRI in treatment-resistant obsessive-compulsive disorder: a randomized controlled treatment study. Int Clin Psychopharmacol. 2005 Jul;20(4):223-6.</citation>
    <PMID>15933483</PMID>
  </reference>
  <reference>
    <citation>Pallanti S, Quercioli L, Paiva RS, Koran LM. Citalopram for treatment-resistant obsessive-compulsive disorder. Eur Psychiatry. 1999 Apr;14(2):101-6.</citation>
    <PMID>10572334</PMID>
  </reference>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 26, 2007</study_first_submitted>
  <study_first_submitted_qc>November 26, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 28, 2007</study_first_posted>
  <last_update_submitted>October 25, 2017</last_update_submitted>
  <last_update_submitted_qc>October 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Sao Paulo</investigator_affiliation>
    <investigator_full_name>Juliana Belo Diniz</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>obsessive compulsive disorder</keyword>
  <keyword>pharmacological treatment</keyword>
  <keyword>quetiapine</keyword>
  <keyword>clomipramine</keyword>
  <keyword>SSRI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Compulsive Personality Disorder</mesh_term>
    <mesh_term>Obsessive-Compulsive Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Quetiapine Fumarate</mesh_term>
    <mesh_term>Clomipramine</mesh_term>
    <mesh_term>Serotonin Uptake Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

